NRx Pharmaceuticals Shares Are Trading Higher After the Company Announced a Statistically Significant Safety Advantage of NRX-101 Compared to the Standard of Care Comparator in Its Recently Completed Clinical Trial in Patients With Suicidal Bipolar...
NRx Pharmaceuticals Shares Are Trading Higher After the Company Announced a Statistically Significant Safety Advantage of NRX-101 Compared to the Standard of Care Comparator in Its Recently Completed Clinical Trial in Patients With Suicidal Bipolar...
nRx Pharmicals 股价上涨，此前该公司在最近完成的自杀性双相情感障碍患者临床试验中宣布，与护理比较标准相比，NRX-101 具有统计学上的显著安全优势...
NRx Pharmaceuticals Shares Are Trading Higher After the Company Announced a Statistically Significant Safety Advantage of NRX-101 Compared to the Standard of Care Comparator in Its Recently Completed Clinical Trial in Patients With Suicidal Bipolar Depression and Plans to Seek Accelerated Approval of NRX-101.
nRx Pharmicals在最近完成的针对自杀性双相抑郁症患者的临床试验中宣布，与护理比较标准相比，NRX-101 具有统计学上的显著安全优势，此后，该公司股价走高，并计划寻求加速批准 NRX-101。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。